maintain equal weight rate share
follow review result updat outlook
result came ahead expect product sale remain sluggish
continu see headwind legaci product
competit price eros focu new product pipelin
encourag howev less optimist regard prospect
durabl respons kra inhibitor therapeut
index competit posit bispecif t-cell engag
cancer overal continu view share fulli valu
rel growth
report result today provid updat
key oper pipelin strateg initi non-gaap ep
ahead consensu total revenu
vs consensu provid ep
guidanc revenu guidanc
total net sale decreas year-over-year
consensu sale vs consensu
consensu prolia vs consensu
repatha vs consensu in-lin sale blincyto
vs consensu consensu sale
vs consensu aimovig vs
consensu non-gaap ep vs prior
focu key trend assumpt note yoy
sale declin yoy volum growth driven lower net sell
price off-set partial higher unit demand sale
grew yoy driven volum growth enbrel beat
driven high net sell price favor chang account
estim partial off-set lower unit demand parsabiv uptak
continu outperform note strong util independ
mid-size dialysi provid amgn hematology/oncolog
portfolio saw yoy growth amgn recent launch bone
franchis product even saw strong uptak us
japan qoq growth aimovig remain lead cgrp
total prescript paid demand increas
follow late acquisit otezla celgen
report strong preliminari sale week ownership
guid histor lower sale vs subsequ quarter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
recent complet acquisit otezla celgen expect sale new market
new indic continu grow brand start april fda render opinion
label expans scalp psoriasi also note otezla eu review behet
diseas compani expect data phase trial patient mild-moder
psoriasi fail topic treatment end expect report phase data
tezepelumab target thymic stromal lymphopoietin tlsp sever uncontrol asthma
partner azn omecamtiv mecarbil chronic heart failur partner
ns high profil first-in-class inhibitor complet enrol
potenti pivot trial relapsed/refractori non-smal cell lung cancer nsclc
month data expect also evalu treatment nave nsclc
codebreak combin keytruda mek inhibitor solid
tumor continu evalu monotherapi advanc
support futur commerci enter strateg collabor develop
blood tissu base companion diagnost
final highlight sever half-lif extend hle bispecif cell engag bite molecul
early-stag develop note compani amass expertis knowledg
defin safe dose/schedul strategi manag cytokin releas syndrom
expect present data bcma hle bite
price target nc
arriv price target appli multipl ep estim risk includ
greater expect eros base biolog busi competit kyproli gener
velcad emerg myeloma treatment failur gain approv proprietari biosimilar
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
